Last 7 days
14.8%
Last 30 days
-81.6%
Last 90 days
-86.7%
Trailing 12 Months
-93.7%
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 30.8M | 31.2M | 21.4M | 0 |
2022 | 6.4M | 6.1M | 23.5M | 29.8M |
2021 | 6.9M | 6.6M | 6.8M | 6.8M |
2020 | 4.4M | 5.5M | 6.0M | 6.5M |
2019 | 9.7M | 6.9M | 6.8M | 4.2M |
2018 | 4.1M | 6.5M | 6.9M | 9.6M |
2017 | 0 | 0 | 0 | 1.7M |
2016 | 0 | 0 | 0 | 0 |
2015 | 38.0K | 60.0K | 82.0K | 104.0K |
2014 | 19.8K | 18.5K | 17.3K | 16.0K |
2013 | 0 | 0 | 0 | 21.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Oct 23, 2023 | monahan joseph | sold | -30,460 | 5.0767 | -6,000 | chief scientific officer |
Sep 06, 2023 | balthaser kevin | bought | 74,971 | 7.9 | 9,490 | chief financial officer |
Sep 01, 2023 | balthaser kevin | acquired | - | - | 1,000 | chief financial officer |
Sep 01, 2023 | balthaser kevin | sold (taxes) | -2,251 | 7.9 | -285 | chief financial officer |
Aug 28, 2023 | loerop james | bought | 99,958 | 6.7976 | 14,705 | chief business officer |
Aug 21, 2023 | monahan joseph | sold | -43,894 | 7.3158 | -6,000 | chief scientific officer |
Aug 01, 2023 | manion douglas j. | sold (taxes) | -43,527 | 9.81 | -4,437 | pres and ceo |
Aug 01, 2023 | manion douglas j. | acquired | - | - | 15,575 | pres and ceo |
Jul 01, 2023 | cawkwell gail | sold (taxes) | -56,070 | 10.37 | -5,407 | chief medical officer |
Jul 01, 2023 | cawkwell gail | acquired | - | - | 15,000 | chief medical officer |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Nov 24, 2023 | DEUTSCHE BANK AG\ | reduced | -85.8 | -10,211,200 | 1,057,020 | -% |
Nov 21, 2023 | Walleye Capital LLC | reduced | -66.05 | -2,747,840 | 794,340 | -% |
Nov 21, 2023 | Walleye Trading LLC | reduced | -29.36 | -256,252 | 224,159 | -% |
Nov 17, 2023 | JACOBS LEVY EQUITY MANAGEMENT, INC | added | 241 | 669,556 | 1,202,040 | 0.01% |
Nov 15, 2023 | MORGAN STANLEY | added | 3.89 | -5,319,050 | 11,634,000 | -% |
Nov 15, 2023 | GSA CAPITAL PARTNERS LLP | reduced | -54.51 | -605,000 | 260,000 | 0.02% |
Nov 15, 2023 | Tudor Investment Corp Et Al | added | - | -116,793 | 227,304 | -% |
Nov 15, 2023 | JANE STREET GROUP, LLC | added | 8.62 | -442,422 | 1,123,810 | -% |
Nov 15, 2023 | Baker Avenue Asset Management, LP | new | - | 233 | 233 | -% |
Nov 15, 2023 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | added | 1.85 | -93,211 | 191,622 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Nov 24, 2023 | tang capital partners lp | 6.1% | 4,338,155 | SC 13G | |
Sep 05, 2023 | citadel advisors llc | 4.7% | 6 | SC 13G | |
Apr 10, 2023 | wellington management group llp | 11.05% | 7,372,601 | SC 13G/A | |
Mar 16, 2023 | biotechnology value fund l p | 2.7% | 1,794,881 | SC 13G | |
Feb 14, 2023 | rock springs capital management lp | 5.94% | 3,961,249 | SC 13G/A | |
Feb 14, 2023 | biotechnology value fund l p | 2.6% | 1,732,725 | SC 13G/A | |
Feb 13, 2023 | foresite capital fund iv, l.p. | 4.2% | 2,808,034 | SC 13G/A | |
Feb 06, 2023 | wellington management group llp | 8.22% | 5,484,013 | SC 13G/A | |
Jan 31, 2023 | blackrock inc. | 7.6% | 5,087,435 | SC 13G/A | |
Apr 25, 2022 | ra capital management, l.p. | 7.1% | 4,398,453 | SC 13G |
Date Filed | Form Type | Document | |
---|---|---|---|
Nov 24, 2023 | SC 13G | Major Ownership Report | |
Nov 13, 2023 | 8-K | Current Report | |
Nov 06, 2023 | 8-K | Current Report | |
Nov 06, 2023 | 10-Q | Quarterly Report | |
Oct 25, 2023 | 4 | Insider Trading | |
Oct 23, 2023 | 144 | Notice of Insider Sale Intent | |
Sep 18, 2023 | 8-K | Current Report | |
Sep 07, 2023 | 4 | Insider Trading | |
Sep 05, 2023 | SC 13G | Major Ownership Report | |
Sep 05, 2023 | 4 | Insider Trading |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
DHR | 163.2B | 29.6B | 12.94% | -16.78% | 27.58 | 5.52 | -5.39% | -12.54% |
IDXX | 43.3B | 3.6B | 23.29% | 25.56% | 52.66 | 12.08 | 7.43% | 22.86% |
A | 37.8B | 7.0B | 20.00% | -14.74% | 33.37 | 5.41 | 5.03% | -14.68% |
DGX | 15.1B | 9.3B | 0.81% | -9.39% | 19.81 | 1.63 | -9.69% | -38.22% |
EXAS | 11.8B | 2.4B | -0.06% | 41.10% | -41.76 | 4.9 | 19.99% | 60.62% |
MID-CAP | ||||||||
CRL | 10.3B | 4.2B | 10.65% | -4.98% | 21.68 | 2.44 | 11.49% | 8.84% |
MEDP | 8.5B | 1.8B | 3.40% | 36.73% | 31.26 | 4.79 | 29.62% | 20.49% |
NTRA | 6.9B | 988.7M | 34.39% | 49.28% | -13.8 | 6.97 | 27.41% | 8.51% |
NEOG | 3.9B | 919.1M | 13.84% | 16.34% | -146.51 | 4.24 | 73.02% | -172.93% |
GH | 3.0B | 535.8M | -7.21% | -48.01% | -7.02 | 5.66 | 24.38% | 26.34% |
SMALL-CAP | ||||||||
CDNA | 522.0M | 297.1M | 48.77% | -26.91% | -5.77 | 1.76 | -6.74% | -21.60% |
ACRS | 72.2M | 21.4M | -81.57% | -93.66% | -0.63 | 3.37 | -8.80% | -39.66% |
AWH | 28.4M | 9.2M | -30.15% | -40.72% | -1.61 | 3.09 | 16.43% | 48.38% |
APDN | 14.3M | 16.1M | 27.59% | -22.38% | -2.03 | 0.89 | -8.51% | 41.77% |
BIOC | 144.4K | - | -82.76% | -93.43% | 0 | 0.76 | -57.78% | -93.13% |
Income Statement (Quarterly) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Revenue | 396.6% | 9,282,000 | 1,869,000 | 2,528,000 | 7,753,000 | 19,018,000 | 1,528,000 | 1,453,000 | 1,501,000 | 1,659,000 | 1,824,000 | 1,777,000 | 1,580,000 | 1,449,000 | 2,046,000 | 1,407,000 | 1,095,000 | 983,000 | 886,000 | 1,263,000 | 3,669,000 | 1,118,000 |
Cost Of Revenue | -18.6% | 848,000 | 1,042,000 | 808,000 | 877,000 | 923,000 | 1,068,000 | 1,155,000 | 1,149,000 | 1,099,000 | 1,263,000 | 1,202,000 | 1,286,000 | 1,189,000 | 1,389,000 | 1,269,000 | 1,027,500 | 826,000 | 994,000 | 1,207,000 | 1,190,000 | 1,067,000 |
Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 160,000 | 435,000 |
Costs and Expenses | 21.3% | 40,859,000 | 33,684,000 | 32,446,000 | 36,832,000 | 39,892,000 | 22,522,000 | 20,360,000 | 24,394,000 | 21,954,000 | 19,830,000 | 30,306,000 | 15,140,000 | 11,914,000 | 13,427,000 | 16,913,000 | 13,058,000 | 23,847,000 | 55,656,000 | 28,314,000 | 13,283,500 | 22,460,000 |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39,198,000 | 33,885,000 |
S&GA Expenses | -14.7% | 7,091,000 | 8,317,000 | 8,790,000 | 7,146,000 | 5,813,000 | 6,075,000 | 6,099,000 | 6,943,000 | 5,979,000 | 5,870,000 | 4,827,000 | 4,898,500 | 3,859,000 | 5,572,000 | 6,200,000 | 6,056,000 | 6,838,000 | 7,469,000 | 7,464,000 | 13,884,500 | 63,000 |
R&D Expenses | -5.5% | 23,876,000 | 25,275,000 | 22,587,000 | 21,072,000 | 23,656,000 | 18,779,000 | 14,306,000 | 14,102,000 | 13,976,000 | 7,897,000 | 7,838,000 | 8,955,500 | 6,240,000 | 6,466,000 | 7,677,000 | 10,825,500 | 16,183,000 | 17,519,000 | 19,643,000 | 18,710,500 | 15,189,000 |
EBITDA Margin | - | - | - | -2.79 | -2.89 | - | -14.67 | -13.99 | -13.30 | - | - | -7.34 | -7.72 | -18.58 | -19.96 | -11.63 | -25.34 | -10.67 | -10.65 | - | - | - |
EBT Margin | - | - | - | -2.82 | -2.92 | - | -14.80 | -14.12 | -13.44 | - | - | -7.49 | -7.92 | -18.93 | -20.53 | -12.14 | -26.86 | -11.27 | -11.14 | - | - | - |
Net Income | 1.0% | -29,261,000 | -29,569,000 | -28,160,000 | -27,635,000 | -19,952,000 | -20,532,000 | -18,789,000 | -22,804,000 | -21,146,000 | -18,161,000 | -28,754,000 | -13,173,000 | -10,659,000 | -11,597,000 | -15,586,000 | -18,594,000 | -55,319,000 | -49,876,000 | -37,565,000 | -38,551,000 | -32,740,000 |
Net Income Margin | 100.0% | - | -3.38 | -3.12 | -2.92 | -3.49 | -13.56 | -12.57 | -13.44 | -11.88 | -10.67 | -9.37 | -7.87 | -9.41 | -18.28 | -14.91 | -38.17 | - | - | - | - | - |
Free Cashflow | 100.0% | - | -20,885,000 | -26,906,000 | -19,220,000 | -7,967,000 | -19,852,000 | -21,133,000 | -17,275,000 | -10,662,000 | -12,247,000 | -12,240,000 | -8,865,000 | -12,454,000 | -10,838,000 | -6,929,000 | -20,656,000 | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Assets | -7.3% | 218 | 236 | 230 | 255 | 268 | 278 | 227 | 251 | 263 | 288 | 161 | 71.00 | 72.00 | 85.00 | 97.00 | 98.00 | 160 | 217 | 253 | 276 | 176 |
Current Assets | -7.4% | 123 | 133 | 184 | 232 | 257 | 259 | 191 | 205 | 206 | 241 | 135 | 57.00 | 58.00 | 71.00 | 83.00 | 84.00 | 145 | 138 | 157 | 179 | 146 |
Cash Equivalents | 25.3% | 39.00 | 31.00 | 45.00 | 45.00 | 62.00 | 68.00 | 36.00 | 27.00 | 54.00 | 113 | 35.00 | 22.00 | 25.00 | 33.00 | 54.00 | 36.00 | 30.00 | 32.00 | 34.00 | 57.00 | 27.00 |
Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 |
Net PPE | -7.1% | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 4.00 | 4.00 | 2.00 | 4.00 |
Goodwill | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.00 | - | - | 19.00 | 19.00 | 19.00 |
Liabilities | 11.0% | 62.00 | 56.00 | 53.00 | 57.00 | 48.00 | 42.00 | 46.00 | 54.00 | 47.00 | 54.00 | 49.00 | 33.00 | 31.00 | 36.00 | 39.00 | 28.00 | 75.00 | 80.00 | 71.00 | 60.00 | 30.00 |
Current Liabilities | 19.7% | 27.00 | 23.00 | 18.00 | 22.00 | 20.00 | 16.00 | 17.00 | 23.00 | 18.00 | 15.00 | 15.00 | 15.00 | 13.00 | 18.00 | 21.00 | 22.00 | 39.00 | 43.00 | 36.00 | 27.00 | 22.00 |
Long Term Debt | - | - | - | - | - | - | - | - | - | - | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | - | 30.00 | 30.00 | 30.00 | 30.00 | - |
Shareholder's Equity | -13.0% | 156 | 180 | 177 | 198 | 220 | 236 | 180 | 197 | 217 | 234 | 112 | 38.00 | 41.00 | 49.00 | 58.00 | 70.00 | 85.00 | 137 | 182 | 215 | 146 |
Retained Earnings | -4.0% | -769 | -740 | -710 | -682 | -654 | -634 | -614 | -595 | -572 | -551 | -533 | -504 | -491 | -480 | -469 | -453 | -434 | -379 | -329 | -292 | -253 |
Additional Paid-In Capital | 0.6% | 927 | 921 | 888 | 881 | 876 | 872 | 795 | 793 | 789 | 785 | 646 | 542 | 532 | 530 | 527 | 524 | 520 | 517 | 512 | 507 | 400 |
Shares Outstanding | 0.1% | 71.00 | 71.00 | 67.00 | 67.00 | 67.00 | 66.00 | 61.00 | 61.00 | 61.00 | 54.00 | 50.00 | 45.00 | 42.00 | 42.00 | 42.00 | 41.00 | 41.00 | 41.00 | 41.00 | 33.00 | 31.00 |
Cashflow (Quarterly) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Cashflow From Operations | -18.9% | -24,557,000 | -20,654,000 | -26,353,000 | -19,115,000 | -7,817,000 | -19,666,000 | -20,969,000 | -17,075,000 | -10,606,000 | -12,221,000 | -12,232,000 | -8,857,000 | -12,150,000 | -10,821,000 | -6,805,000 | -20,390,000 | -23,359,000 | -21,378,000 | -31,318,000 | -27,248,000 | -29,858,000 |
Share Based Compensation | -8.8% | 5,948,000 | 6,522,000 | 6,806,000 | 4,813,000 | 4,188,000 | 3,692,000 | 2,346,000 | 3,851,000 | 3,702,000 | 3,832,000 | 2,675,000 | 2,504,000 | 1,941,000 | 3,309,000 | 3,453,000 | 3,181,000 | 3,320,000 | 4,814,000 | 4,862,000 | 4,956,000 | 4,707,000 |
Cashflow From Investing | 265.5% | 32,534,000 | -19,662,000 | 25,798,000 | 2,702,000 | 1,217,000 | -21,223,000 | 29,932,000 | -9,176,000 | -37,672,000 | -45,470,000 | -75,314,000 | -2,305,000 | 5,237,000 | -10,487,000 | 13,942,000 | 56,438,000 | 21,673,000 | 18,952,000 | 8,616,000 | -70,506,000 | 10,394,000 |
Cashflow From Financing | -Infinity% | -87,000 | - | - | 37,000 | -11,000 | 72,811,000 | 30,000 | -2,000 | -11,567,000 | 135,871,000 | 100,750,000 | 7,829,000 | -278,000 | -97,000 | 10,918,000 | -30,009,000 | -70,000 | -117,000 | -120,000 | 128,183,000 | 19,000 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Revenues: | ||||
Total revenue | $ 9,282 | $ 19,018 | $ 13,679 | $ 21,999 |
Costs and expenses: | ||||
Cost of revenue | 848 | 923 | 2,698 | 3,146 |
Research and development | 23,876 | 23,656 | 71,738 | 56,741 |
General and administrative | 7,091 | 5,813 | 24,198 | 17,987 |
Licensing | 7,344 | 7,300 | 8,955 | 7,300 |
Revaluation of contingent consideration | 1,700 | 2,200 | (600) | (2,400) |
Total costs and expenses | 40,859 | 39,892 | 106,989 | 82,774 |
Loss from operations | (31,577) | (20,874) | (93,310) | (60,775) |
Other income, net | 2,316 | 922 | 6,320 | 1,502 |
Net loss | $ (29,261) | $ (19,952) | $ (86,990) | $ (59,273) |
Net loss per share, basic | $ (0.41) | $ (0.30) | $ (1.25) | $ (0.92) |
Net loss per share, diluted | $ (0.41) | $ (0.30) | $ (1.25) | $ (0.92) |
Weighted average common shares outstanding, basic | 70,807,934 | 66,675,337 | 69,452,495 | 64,718,008 |
Weighted average common shares outstanding, diluted | 70,807,934 | 66,675,337 | 69,452,495 | 64,718,008 |
Other comprehensive loss: | ||||
Unrealized loss on marketable securities, net of tax of $0 | $ (18) | $ (139) | $ (232) | $ (1,241) |
Total other comprehensive loss | (18) | (139) | (232) | (1,241) |
Comprehensive loss | (29,279) | (20,091) | (87,222) | (60,514) |
Contract research | ||||
Revenues: | ||||
Total revenue | 705 | 1,090 | 2,469 | 3,529 |
Licensing | ||||
Revenues: | ||||
Total revenue | $ 8,577 | 17,898 | $ 11,210 | 18,378 |
Other | ||||
Revenues: | ||||
Total revenue | $ 30 | $ 92 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 39,040 | $ 45,277 |
Short-term marketable securities | 64,012 | 172,294 |
Accounts receivable, net | 346 | 484 |
Prepaid expenses and other current assets | 19,670 | 13,495 |
Total current assets | 123,068 | 231,550 |
Marketable securities | 83,944 | 12,242 |
Property and equipment, net | 1,764 | 1,099 |
Intangible assets | 6,917 | 6,973 |
Other assets | 2,661 | 2,732 |
Total Assets | 218,354 | 254,596 |
Current liabilities: | ||
Accounts payable | 9,648 | 10,351 |
Accrued expenses | 15,160 | 8,701 |
Current portion of lease liabilities | 310 | 684 |
Discontinued operations | 2,202 | 2,202 |
Total current liabilities | 27,320 | 21,938 |
Other liabilities | 1,834 | 1,570 |
Contingent consideration | 32,500 | 33,100 |
Deferred tax liability | 367 | 367 |
Total liabilities | 62,021 | 56,975 |
Commitments and contingencies (Note 14) | ||
Stockholders' Equity: | ||
Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at September 30, 2023 and December 31, 2022 | ||
Common stock, $0.00001 par value; 200,000,000 and 100,000,000 shares authorized at September 30, 2023 and December 31, 2022, respectively; 70,818,954 and 66,688,647 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 1 | 1 |
Additional paid-in capital | 926,766 | 880,832 |
Accumulated other comprehensive loss | (1,129) | (897) |
Accumulated deficit | (769,305) | (682,315) |
Total stockholders' equity | 156,333 | 197,621 |
Total liabilities and stockholders' equity | $ 218,354 | $ 254,596 |
CEO | Dr. Douglas J. Manion Frcp(C), M.D. |
---|---|
WEBSITE | www.aclaristx.com |
EMPLOYEES | 100 |